Loading...
Market
What will be the outcome of SENTI-202 Phase 1 trial by the end of 2025?
2
Resolution / Starting Odds
Positive results with MRD-negative CR • 25%
Mixed results • 25%
Negative results • 25%
Trial discontinued • 25%
Senti Biosciences official press releases or clinical trial registries
Story
Senti Biosciences Reports Positive SENTI-202 Trial Data, Secures $37.6M Financing, and Sees 139.8% Stock Increase
Dec 2, 2024, 01:20 PM
Senti Biosciences, Inc. announced positive initial clinical data from its Phase 1 trial of SENTI-202, a logic-gated, selective CD33/FLT3-targeting CAR-NK cell therapy for relapsed/refractory hematologic malignancies, including acute myeloid leukemia (AML). The trial showed promising results, with two out of three patients achieving minimal residual disease (MRD)-negative complete remission (CR) and a generally favorable safety profile. Additionally, the company secured $37.6 million in an oversubscribed private placement equity financing and appointed Fran Schulz to its Board of Directors as a new member and audit chair. These developments have led to a significant pre-market stock price increase of 139.8%.
View original story
Similar markets
Positive outcome with significant efficacy • 25%
Mixed outcome with limited efficacy • 25%
Negative outcome with no efficacy • 25%
Trial terminated early due to safety concerns • 25%
Successful with no major adverse effects • 25%
Successful with minor adverse effects • 25%
Unsuccessful due to lack of efficacy • 25%
Unsuccessful due to major adverse effects • 25%
Meets primary endpoint • 25%
Fails primary endpoint • 25%
Mixed results • 25%
Trial not completed by end of 2025 • 25%
Significant improvement • 25%
Moderate improvement • 25%
No improvement • 25%
Worse outcomes • 25%
Positive efficacy and safety results • 25%
Positive efficacy, but safety concerns • 25%
Negative efficacy, but good safety • 25%
Negative efficacy and safety concerns • 25%
Positive results • 25%
Negative results • 25%
Inconclusive results • 25%
Trial not completed • 25%
Complete Response • 25%
Partial Response • 25%
Stable Disease • 25%
Progressive Disease • 25%
Significant improvement • 25%
Moderate improvement • 25%
No improvement • 25%
Worsening condition • 25%
Positive results for B-cell malignancies • 25%
Positive results for autoimmune diseases • 25%
Negative results for both • 25%
Mixed results • 25%
Successful with significant efficacy • 25%
Successful with moderate efficacy • 25%
Successful with minimal efficacy • 25%
Unsuccessful • 25%
Positive results • 25%
Negative results • 25%
Mixed results • 25%
No results announced • 25%
